RarePlex® ARv7/SYP CTC Panel Kit    

 

Immunofluorescent detection of androgen receptor splice variant 7 (ARv7) / Synaptophysin expression by circulating tumor cells.

 

Prostate cancer (PC) is the second most common type of malignancy and one of the leading causes of cancer deaths in men worldwide.1,5 As androgen-mediated signaling is the predominant driver of PC proliferation,2 the androgen receptor (AR) is an important therapeutic target in prostate cancer where antiandrogens have been developed, primarily targeting the ligand-binding domain of the protein.3 Unfortunately, some patients may not benefit from the inhibition of AR activity or may develop secondary resistance. This resistance is observed in patients with circulating tumor cells (CTCs) containing androgen receptor splice variant 7 (Arv7), which lacks the ligand-binding domain, and correlates with poor treatment outcomes.

 

Although antiandrogen resistance is mediated by AR signaling in some patients, the incidence of AR-independent PC is on the rise, in response to the introduction of more effective antiandrogens.6 One form of AR-independent PC, neuroendocrine PC (NEPC) is an aggressive form of PC that usually occurs in later stages of the disease, with resistance to earlier treatments6 and exhibits the expression of neuroendocrine markers, such as the most commonly expressed NEPC marker, Synaptophysin (SYP).4

 

RareCyte’s ARv7 and SYP circulating tumor cell assay provides highly accurate, repeatable, and precise results for circulating tumor cell count, ARv7 and SYP biomarker expression, and is suitable for use in large, multi-center clinical trials of PC. This assay enables a blood-based investigation of two prominent mechanisms by which tumors become resistant to second line endocrine therapies. The assay includes processing blood to slides with the AccuCyte® Sample Preparation System followed by staining with the RarePlex 0919-LB ARv7/SYP CTC Panel Kit and imaging on a CyteFinder® Instrument. Machine learning enabled analysis and scoring maximizes reviewer concordance.

 

 

 

 

This ARv7/SYP assay, deployed on RareCyte’s circulating tumor cell analysis platform, provides:

 

  •  Simple processing of blood to slides for sample banking

  •  Convenient pause points in workflow enable sample control and transport

  •  Flexible sample handling – processing and analysis may be performed at the same site or at a separate clinical research 

     laboratory

  •  Accurate and highly reproducible results

  •  Worldwide network of contract research organizations (CROs) to support global clinical trials

 

RareCyte RarePlex ARv7/Synaptophysin CTC Panel Kit, Leica (SYTOX)     24-1282-001

This 5-channel kit ( Version: 0919-LB) detects ARv7 and SYP in CTCs. The kit contains a nuclear dye and antibodies detecting CD45 (to exclude WBC), CK, EpCAM, ARv7 and SYP. Samples are stained by a Leica® BOND® RX andimaged on CyteFinder®.

 

RareCyte RarePlex 22Rv1 spike-in CTC Control Slide, 10-Pack      24-1279-000

Contain monolayer of buffy coat and spiked-in 22Rv1 cells. Compatibility: 24-1250-001, 24-1281-001, 24-1282-001, 24-1287-002.